EV growth accelerates in London despite national decline in buyer interest
London Hydro is seeing an uptick in electric vehicle adoption but reports show fewer Canadians are considering buying them, CTV's Reta Ismail investigates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Sellers accept offer on North York townhouse after second attempt at the market
70 Castlebury Cres. No. 9, Toronto Asking price: $829,900 (March, 2025) Previous asking price: $825,000 (November, 2024) Selling price: $820,000 (March, 2025) Taxes: $3,168 (2024) Property days on market: 44 Listing agent: Bill Thom, Re/Max Realtron Realty Inc. The owners of this three-bedroom townhouse near Old Cummer GO station were not under any pressure to sell, which made it easier for them to reject the first offer for the property, for $815,000, before Christmas. With no other offers forthcoming, they took the property off the market for a few months, returning with a higher asking price in March. An offer of $820,000 was accepted. 'If you look at the math, they [would have been] better off if they had taken the $815,000 with the heating costs, maintenance fees, time and money [factored in],' said agent Bill Thom. Part of a roughly 50-year-old townhouse complex, this end unit has a multilevel layout with a street-level entrance, a built-in garage and a private, south-facing yard. The front door opens into a foyer with a short flight of steps down to a recreation area. Another set of stairs leads up to a living room with access to a patio and open sightlines into a dining area and eat-in kitchen on the next level. The bedrooms and two bathrooms are on the top two floors. Monthly condominium fees are $660 and cover water usage. 'It's a good area with a very good school, and we had an end unit, which is very rare,' Mr. Thom said. 'The backyard is facing south, so you get a lot of light.'
Globe and Mail
23 minutes ago
- Globe and Mail
Methanex Corporation Receives Regulatory Approval for the Acquisition of OCI Global's Methanol Business
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Methanex Corporation (TSX:MX) (Nasdaq:MEOH) announced today that the regulatory review period under the U.S. Hart-Scott-Rodino Antitrust Act has lapsed. Accordingly, all regulatory approvals required for Methanex to close its previously announced acquisition of OCI Global's international methanol business have been obtained. The transaction is expected to close on June 27, 2025, and remains subject to the satisfaction of customary closing conditions. "We are pleased to have received regulatory clearance and look forward to closing the transaction and welcoming new team members to Methanex." said Rich Sumner, President and CEO of Methanex. "Given our extensive integration planning, we expect to move quickly upon closing to deliver the strategic benefits of this acquisition." Methanex is a Vancouver-based, publicly traded company and is the world's largest producer and supplier of methanol globally. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol 'MX' and on the Nasdaq Stock Market in the United States under the trading symbol 'MEOH'. Methanex can be visited online at Inquiries Sarah Herriott Director, Investor Relations Methanex Corporation 604-661-2600 or Toll Free: 1-800-661-8851 Forward Looking Statements This First Quarter 2025 Management's Discussion and Analysis ("MD&A") as well as comments made during the First Quarter 2025 investor conference call contain forward-looking statements with respect to us and our industry. These statements relate to future events or our future performance. All statements other than statements of historical fact are forward-looking statements. Statements that include the word "expects," or other comparable terminology and similar statements of a future or forward-looking nature identify forward-looking statements. More particularly and without limitation, any statements regarding the following are forward-looking statements: anticipated closing date of the OCI acquisition and the expected benefits of the OCI acquisition, including benefits related to expected synergies and commodity diversification, anticipated synergies and Methanex's ability to achieve such synergies following closing of the OCI acquisition, and expected increase in methanol production of assets to be acquired as part of the OCI acquisition. We believe that we have a reasonable basis for making such forward-looking statements. The forward-looking statements in this document are based on our experience, our perception of trends, current conditions and expected future developments as well as other factors. Certain material factors or assumptions were applied in drawing the conclusions or making the forecasts or projections that are included in these forward-looking statements, including, without limitation, future expectations and assumptions concerning the following: future expectations and assumptions concerning the receipt of all regulatory approvals required to complete the OCI acquisition, and Methanex's ability to realize the expected strategic, financial and other benefits of the OCI acquisition in the timeframe anticipated or at all. However, forward-looking statements, by their nature, involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The risks and uncertainties primarily include those attendant with producing and marketing methanol and successfully carrying out major capital expenditure projects in various jurisdictions, including, without limitation: failure to complete the OCI acquisition in accordance with the material terms of the OCI acquisition agreement or at all, failure to close the OCI acquisition credit facility, unforeseen difficulties in integrating the business operations or assets purchased pursuant to the OCI acquisition into our business and operations, failure to realize the expected strategic, financial and other benefits of the OCI acquisition in the timeframe anticipated or at all, and unexpected costs or liabilities associated with the OCI acquisition. Having in mind these and other factors, investors and other readers are cautioned not to place undue reliance on forward-looking statements. They are not a substitute for the exercise of one's own due diligence and judgment. The outcomes implied by forward-looking statements may not occur and we do not undertake to update forward-looking statements except as required by applicable securities laws.
National Post
36 minutes ago
- National Post
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
Article content Article content Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Article content Biologics License Application (BLA) filing planned for mid-2026 remains on track Article content EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Article content Cash and marketable securities of $251.5 million expected to provide runway into 2027 Article content BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, or 'enGene' or the 'Company'), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. Article content 'We have seen strong enrollment in the pivotal cohort of our LEGEND study,' said Ron Cooper, Chief Executive Officer of enGene. 'This positions us to stay on track for our planned trial updates across all cohorts in the second half of 2025 and a potential BLA filing in mid-2026, advancing our goal to introduce a novel, non-viral therapy that could redefine treatment for patients with high-risk non-muscle invasive bladder cancer.' Article content Recent Corporate Updates Article content Key executive hires and management appointments: Article content In May 2025, the Company announced the appointment of Amy Pott as Chief Global Commercialization Officer. Ms. Pott joined enGene from Astellas Pharma, where she most recently served as Senior Vice President, Strategic Brand Marketing, Ophthalmics and Rare Diseases, and previously as Head of Commercial, Gene Therapies. She will serve as the Company's first dedicated executive for commercialization planning and execution. Article content LEGEND study enrollment update: Article content Over the course of the first and second quarters of 2025, the Company expanded its clinical footprint for the LEGEND study with the addition of trial sites in Europe and Asia. The pivotal cohort evaluating detalimogene Article content Article content voraplasmid (also known as detalimogene, and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) remains on track for our planned BLA in mid-2026. The Company expects to provide an update from LEGEND's pivotal cohort in the second half of 2025. Article content European Medicines Agency (EMA) Scientific Advice: Article content The Company shared detalimogene preclinical and clinical data through the EMA Scientific Advice process. During the dialogue, EMA indicated that it broadly agrees that these data could be suitable for a Conditional Marketing Authorization Application (CMA) submission for detalimogene in BCG-unresponsive NMIBC with CIS assuming a positive benefit-risk ratio. Article content BIOTECanada Gold Leaf Biotech Company of the Year Award Winner: Article content The Biotech Company of the Year Award recognizes a company that is transforming the future of healthcare through groundbreaking advancements. The Company is proud and honored to be recognized with this distinction. Article content Second Quarter 2025 Financial Results Article content As of April 30, 2025, cash, cash equivalents and marketable securities were $251.5 million. The Company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses, debt obligations and capital expenditures into 2027. Article content Three Months ended April 30, 2025 Article content Total operating expenses were $27.1 million for the three months ended April 30, 2025, compared to $17.3 million for the three months ended April 30, 2024. Research and development expenses increased by $10.4 million, mainly due to increasing manufacturing and clinical costs related to our pivotal LEGEND study and personnel-related costs. General and administrative expenses decreased by $0.5 million, primarily driven by decreased reliance on professional services to support the Company's operation as a publicly traded company. Article content For the three months ended April 30, 2025, net loss attributable to common shareholders was approximately $25.8 million, or $0.51 per share, compared to approximately $15.0 million, or $0.38 per share, for the same period for the three months ended April 30, 2024. The increase in net loss is mainly attributed to the increase in operating expenses, partially offset by net interest income earned during the period. Article content About Non-Muscle Invasive Bladder Cancer (NMIBC) Article content Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on our healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can take the form of papillary outgrowths from the bladder wall, which are typically resected, or carcinoma in situ (CIS), flat, multifocal lesions that are unable to be resected, and the two can co-occur. About 75-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50-70%) and are subject to full removal of the bladder (cystectomy) as a curative but life-altering next step. Article content About Detalimogene Article content Detalimogene is a novel, investigational, non-viral genetic medicine for patients with high-risk, NMIBC, including BCG-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response. Article content Detalimogene was developed using the Company's Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, simplify safe handling and cold storage complexities, and streamline both manufacturing processes and administration paradigms. Article content Detalimogene has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive CIS NMIBC, with or without resected papillary tumors, who are unable to undergo cystectomy. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Article content About the Pivotal LEGEND Trial Article content Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk, NMIBC. LEGEND's pivotal cohort (Cohort 1) consists of approximately 100 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary disease) and is designed to serve as the basis of the Company's planned Biologics License Application (BLA) filing. In addition to this pivotal cohort, LEGEND includes three additional cohorts, including NMIBC patients with CIS who are naïve to treatment with BCG (Cohort 2a); NMIBC patients with CIS who have been exposed to BCG but have not received adequate BCG treatment (Cohort 2b); and BCG-unresponsive high-risk NMIBC patients with papillary-only disease (Cohort 3). The LEGEND trial is actively enrolling patients with sites participating in the USA, Canada, Europe, and the Asia-Pacific region. Article content About enGene Article content enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit Article content Forward-Looking Statements Article content Certain statements contained in this press release may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and 'forward-looking information' within the meaning of Canadian securities laws (collectively, 'forward-looking statements'). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's management teams' expectations, hopes, beliefs, intentions, goals, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate', 'appear', 'approximate', 'believe', 'continue', 'could', 'estimate', 'expect', 'foresee', 'intends', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would', and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: our plans regarding the timing of our planned BLA submission to the Food and Drug Administration, our expectations as to the timing and anticipated results of the LEGEND study, including the timing of preliminary data or other updates, our expectations regarding a potential CMA submission to the EMA, our expectations regarding completion of enrollment in the LEGEND study, including the timing, the potential benefits of detalimogene, including its potential impact on the treatment landscape and attractiveness to patients and physicians, the potential benefits of medicines developed with the DDX platform and the expected period over which we estimate our cash, cash equivalents and marketable securities will be sufficient to fund our current operating plan. Article content Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company's clinical development plans and ability to secure regulatory approval on anticipated timelines, and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ('SEC') on EDGAR, including those described in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024 (copies of which may be obtained at or Article content You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Article content Three Months Ended April 30, Six Months Ended April 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 20,209 $ 9,855 $ 40,183 $ 15,493 General and administrative 6,915 7,455 13,554 12,590 Total operating expenses 27,124 17,310 53,737 28,083 Loss from operations 27,124 17,310 53,737 28,083 Total other (income) expense, net (1,549 ) (2,347 ) (3,564 ) (2,379 ) Net loss before income tax 25,575 14,963 50,431 25,704 Provision for (recovery of) income tax 240 21 258 (9 ) Net loss $ 25,815 $ 14,984 $ 50,431 $ 25,695 Other comprehensive loss: Unrealized gain on available-for-sale investments $ (306 ) $ — $ (450 ) $ — Total comprehensive loss $ 25,509 $ 14,984 $ 49,981 $ 25,695 Net loss attributable to common shareholders, basic and diluted 25,815 14,984 50,431 25,695 Weighted-average common shares outstanding, basic and diluted 51,019,363 39,443,768 50,997,987 31,186,238 Net loss per share of common shares, basic and diluted $ 0.51 $ 0.38 $ 0.99 $ 0.82 Article content enGene Holdings Inc. Article content Article content Article content Article content
